National and Kapodistrian University of Athens
Φαρμακολογική μελέτη της αντινεοπλασματικής δράσης νέων παραγώγων τριαζολο-[3,4-b]-1,3,4-θειαδιαζολίων
Abstract
dc:descriptionThe fusion of 1,2,4-triazole and 1,3,4-thiadiazole rings generated a category of therapeutic agents with a broad spectrum of pharmacological properties including anticancer. The significant chemical potentialities of 1,2,4-triazoles and 1,3,4-thiadiazoles led to the design and synthesis of new 3,6-disubstituted 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazoles derivatives some of which stood out for their in vitro and in vivo anticancer activity. The present study aims to the in vitro evaluation of the pharmacological anticancer activity of novel compounds and screening of the most effective, investigation of protein targets and finally in vitro estimation of their impact on the predictive biomarkers, MSI (microsatellite instability), PD-L1 (programmed death ligand-1) and TMB (tumor mutation burden). Additionally, the apoptotic activity and the effect on cell cycle progression induced by the most effective compound were studied. For the purpose of this study, human cancer cell lines were used: five colorectal (DLD-1, HT-29, LoVo, LS174T, SW403) and two prostate (DU-145, PC-3) with different MSI phenotypes. The in vitro antineoplastic activity of KA25, KA26, KA39, SF29, and SF30 was assessed according to MTT assay, while the effect of KA39 on apoptosis and cell cycle was determined by staining assays such as annexin V/7-AAD and propidium iodide, respectively. In the context of the antineoplastic activity of the tested compounds, in silico studies were carried out according to which TopIIα and Akt1/2 proteins constitute potential therapeutic targets. In case of TopIIα, the inhibitory effect of KA25, KA26, and KA39 was investigated both on its catalytic activity (plasmid-based topoisomerase II drug screening kit) and its phosphorylation (Human Phospho-TOP2A/Topoisomerase II Alpha Cell-Based Phosphorylation ELISA Kit). As far as it concerns Akt1/2 kinases, KA25 and KA39 were estimated as potential inhibitors by intracellular flow cytometry. The impact of the most effective derivative, KA39, on the immunogenic predictive biomarkers, PD-L1, MSI και TMB, was studied in MSI-H and MSS cancer cells according to extracellular flow cytometry, PCR analysis conducted in the five microsatellite systems of Bethesda panel and targeted sequencing (Oncomine™ Tumor Mutation Load Assay), respectively. According to MTT results, among all the tested triazolo-[3,4-b]-thiadiazoles derivatives, KA39 emerged as the most effective due to its significant cytostatic and cytotoxic activity induced in all cancer cell lines (P<0.001). The administration of KA39 in cancer cells induced early and late apoptosis, as well as caused cell cycle arrest at phase S (P<0.001). The KA39-induced formation of supercoiled DNA during the relaxation reaction of plasmid DNA in combination with the statistically significant reduction of TopIIα phosphorylation indicates that KA39 belongs to TopIIα inhibitors. Furthermore, a remarkable inhibition of Akt1/2 phosporylation was impelled upon treatment with KA25 and KA39 (P<0.01). Moreover, the effect of KA39 triggered the overexpression of the immunoregulatory molecule, PD-L1, in MSI-H and MSS cancer cells. Additionally, the MMR mechanism was destabilized, particularly in MSI-H and to a lesser extent in MSS cancer cell lines. Finally, comparing control groups with the cells that received KA39, no alterations were observed in TMB.To conclude, among the new triazolo-[3,4-b]-thiadiazoles derivatives, the chemical compound KA39 was proved as the most effective, according to the in vitro cytostatic and cytotoxic activity induced in all the tested cancer cell lines. The current findings imply that KA39 behaves as a multitarget drug, inducing a remarkable antineoplastic activity as well as triggering the expression of the PD-L1 ligand and provoking simultaneously disorders in the functionality of the MMR mechanism, which are reflected in MSI phenotype. Conclusively, KA39 derivative seems to be a very promising anticancer agent with possibilities for further development in clinical practice and cancer chemo-immunotherapy.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Sagredou, Sofia
- Σαγρέδου, Σοφία
Subjects
dc:subject × 22- 1,2,4-τριαζόλια
- 1,3,4-θειαδιαζόλια
- Αντικαρκινική δράση
- Τοποϊσομεράση ΙΙα
- Kινάση Akt
- Μικροδορυφορική αστάθεια
- PD-L1
- Φορτίο μεταλλαγών όγκου
- 1,2,4-triazoles
- 1,3,4-thiadiazoles
- Anticancer activity
- Topoisomerase IIα
- AKT kinase
- Microsatellite instability ( MSI )
- Programmed death ligand 1
- Tumor mutation burden
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Φαρμακολογία και Φαρμακευτική
- Basic Medicine
- Medical and Health Sciences
- Pharmacology and Pharmacy
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/51402